A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)
- Status
- UNKNOWN
- Phase
- N/A
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Status
- RECRUITING
- Phase
- N/A
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
- Status
- COMPLETED
- Phase
- PHASE3
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Status
- RECRUITING
- Phase
- PHASE2
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
- Status
- RECRUITING
- Phase
- PHASE1
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
- Status
- COMPLETED
- Phase
- N/A
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1